TrianglePhysician's Choice (NCT06942442)
Physician's Choice trial for HLA-A*0201 Positive Cells Present (NCT06942442). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with HMB-45-positive clear cell sarcoma that is unresectable or metastatic. Disease must have progressed recently, or be newly diagnosed.
The idea: tebentafusp links gp100-bearing tumor cells to T cells. HLA-A*02:01-positive patients receive weekly intravenous doses. Negative patients enter a separate physician-choice treatment group. Research biopsies accompany tebentafusp when safe and feasible.
This phase 2 study plans 47 patients. The Sarcoma Alliance for Research through Collaboration sponsors three recruiting US sites: Los Angeles, Chicago and New York. Researchers measure progression-free survival.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.